Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
An HIV-specific model underestimated the risk for heart attacks and other cardiovascular events.
Gilead Sciences presented findings from several studies of the single-tablet antiretroviral regimen at a recent scientific meeting.
Researchers are surprised and concerned that a strain of HIV that is so broadly resistant to treatment even has the capacity to transmit.
Two-drug antiretroviral regimens suppress viral load, but three-drug combos may offer additional benefits.
The observation that there have been Covid-19 infections in HIV+ persons on TDF/TAF argues against a complete protection from these agents.
HIV-positive people appear no more likely to contract the new coronavirus or to become seriously ill.
New database will collect information about cases of the novel coronavirus among people living with HIV.
A recent small study examined pairings of antiretrovirals and statins or blood pressure medications.
What’s more, reports that Kaletra can fight the novel coronavirus have not been confirmed.
Aim is to reduce viral load in those infected in order to put brake on spread
A major plus of the implant is that it can be easily removed if necessary.
The antiretroviral GS-6207 is injected under the skin and would need to be combined with other meds to fully suppress HIV.
More high-quality evidence is needed to determine how this class of HIV medications may affect weight gain.
However, the regimen appears much less potent for those who aren’t virally suppressed.
Researchers have presented 96-week results from an advanced trial of Symtuza compared with Prezcobix plus Truvada.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.